@article{5ad333b9dd654b1eabe981fcd66c6486,
title = "Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia",
author = "Martins, \{L. R.\} and P. L{\'u}cio and A. Mel{\~a}o and I. Antunes and Cardoso, \{B. A.\} and R. Stansfield and Bertilaccio, \{M. T.S.\} and P. Ghia and D. Drygin and Silva, \{M. G.\} and Barata, \{J. T.\}",
note = "Funding Information: We are grateful to all the patients who contributed to this study. We thank Dr Riccardo Dalla-Favera for providing the MO1043 cell line and Dr John Byrd for providing the WaC3CD5 cell line. We also thank the Helena Ala{\`i}z (cytogenetics section of the Hemato-oncology lab at Instituto Portugu{\^e}s de Oncologia). This work was mainly supported by the grant PIC/IC/83193/2007 from Fundac¸{\~a}o para a Ci{\^e}ncia e a Tecnologia; and also by Associazione Italiana per la Ricerca sul Cancro AIRC (Investigator Grant and Special Program Molecular Clinical Oncology {\textendash} 5 per mille \#9965), Ricerca Finalizzata 2010 {\textendash} Ministero della Salute, Roma. LRM received an FCT-SFRH PhD fellowship.",
year = "2014",
doi = "10.1038/leu.2013.232",
language = "English (US)",
volume = "28",
pages = "179--182",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Springer Nature",
number = "1",
}